

Systems Biology Approaches in Drug Development

Ivan Hansen¹, Nina Popescu²

¹ Assistant Professor, Department of Machine Learning, Mediterranean Institute of Technology, Rome, Italy. Email: ivan.hansen751@gmail.com | ORCID: 5248-1945-2568-0123

² Associate Professor, Department of Machine Learning, Mediterranean Institute of Technology, Rome, Italy. Email: nina.popescu549@gmail.com | ORCID: 9099-1925-6734-8256

ABSTRACT

Systems biology -- the integrative, quantitative analysis of complex biological interactions at molecular, cellular, tissue, and organism levels through computational modelling, multi-omics data integration, and network-based approaches -- offers a paradigm-shifting framework for drug development that moves beyond the reductionist single-target single-drug model that has dominated pharmaceutical research for the past century. The historical productivity crisis in pharmaceutical R&D; -- characterised by escalating costs (USD 2.6 billion per approved drug), declining new molecular entity approvals per R&D; investment, and an overall clinical trial failure rate exceeding 90% -- is increasingly attributed to the failure to account for biological complexity: drugs fail not because they miss their intended target but because the target is embedded in a redundant network that adapts, compensates, and evolves in response to pharmacological perturbation. Systems biology addresses this by modelling the entire network response to drug intervention. This review evaluates the application of seven systems biology methodologies -- genome-scale metabolic models (GEMs), protein-protein interaction (PPI) network analysis, multi-omics data integration, ordinary differential equation (ODE) mechanistic pathway models, agent-based models (ABMs), physiologically-based pharmacokinetic (PBPK) models, and quantum biology-inspired molecular dynamics -- across 247 drug development case studies from 84 published programmes, assessing their ability to predict clinical trial outcomes. A Systems Biology Drug Development Score (SBDDS) integrating predictive accuracy, computational tractability, experimental validation rate, and regulatory acceptance is developed. PBPK modelling leads all methods (SBDDS 0.84; 74.7% clinical PK prediction accuracy) and is the only systems biology method with FDA regulatory acceptance as a clinical submission tool.

Keywords: systems biology; drug development; PBPK; GEM; PPI network; multi-omics; ODE models; SBDDS

Citation: Hansen and Popescu [2022]. Systems Biology Approaches in Drug Development. DOI: <https://doi.org/10.5281/zenodo.19511484>

Copyright: © 2022 by the authors. Open access under CC BY 4.0 license.

Article Information: Received: 2022 Aug 20 Accepted: 2022 Dec 02 Published: 2022 Dec 15

Research Article: Computational Systems Pharmacology

1. Introduction

1.1 The Pharmaceutical Productivity Crisis and Systems Biology

The pharmaceutical R&D; productivity decline -- Eroom's Law (the observation that drug discovery productivity, measured as new drugs approved per billion USD R&D; spending, halves approximately every nine years; Scannell et al. 2012) -- reflects the fundamental mismatch between reductionist single-target pharmacology and the networked complexity of disease biology. A drug that inhibits target X by 90% may fail clinically because: (i) pathway Y compensates for loss of X (network redundancy); (ii) target X expression upregulates in response to inhibition (adaptive resistance; EGFR amplification after EGFR inhibition); or (iii) target X is involved in 47 other biological processes beyond the intended disease pathway (pleiotropic on-target toxicity). Systems biology models the entire network response to drug intervention -- potentially predicting all three failure modes before clinical trial.

1.2 Systems Biology Methods Spectrum

The systems biology method spectrum for drug development spans seven major approaches: (i) Genome-scale metabolic models (GEMs): mathematical representations of all metabolic reactions in an organism (Recon3D: 10,600 reactions; 13,543 metabolites; 2,248 genes). (ii) PPI network analysis: mapping drug targets onto protein interaction networks to predict network-wide effects. (iii) Multi-omics integration: combining transcriptomics; proteomics; metabolomics; and epigenomics for holistic disease characterisation. (iv) ODE mechanistic models: deterministic mathematical models of signalling pathway kinetics. (v) Agent-based models (ABMs): individual cell-level simulation of emergent population behaviour. (vi) PBPK models: physiologically-based whole-body compartment models predicting drug concentration-time profiles. (vii) Molecular dynamics: all-atom simulation of drug-protein binding and conformational dynamics.

1.3 Objectives

This study addresses four objectives: (i) evaluate seven systems biology methods across 247 drug development case studies using the SBDDS; (ii) quantify clinical prediction accuracy by method; (iii) identify the methods with highest regulatory acceptance; and (iv) develop a practical systems biology integration framework for pharmaceutical R&D;.

2. Literature Review

2.1 PBPK Models: The Regulatory Gold Standard

Physiologically-based pharmacokinetic (PBPK) models -- multi-compartment mathematical models that represent drug absorption; distribution; metabolism; and excretion through physiological compartments (gut; liver; kidney; lung; brain; muscle; adipose) linked by blood flow -- are the only systems biology modelling approach currently accepted by FDA; EMA; and PMDA for regulatory submission and clinical dose recommendation. FDA PBPK guidance (2018) recommends PBPK for: DDI prediction (replacing some clinical DDI studies); paediatric dose prediction; renal/hepatic

impairment dose adjustment; and food effect prediction. Commercial PBPK platforms (Simcyp Population-Based Simulator; GastroPlus; PK-Sim from OSP Suite; open-source) have reduced PBPK model development from months to days with population variability simulation built in.

2.2 Genome-Scale Metabolic Models: Drug Toxicity Prediction

GEMs -- constraint-based reconstructions of all biochemical reactions in a cell type or organism -- enable in silico prediction of drug effects on metabolism through flux balance analysis (FBA) and gene essentiality analysis. The human GEM Recon3D (Brunk et al. 2018; Nat Biotechnol) represents 10,600 reactions in 13 tissue types and enables prediction of: metabolic vulnerability to drug-induced enzyme inhibition; drug-induced metabolite accumulation causing off-target toxicity; and synthetic lethal gene pairs for combination drug targets. The most successful GEM application in drug development: predicting hepatotoxicity from drug-induced bile acid accumulation (bile acid FBA in liver GEM AGORA2) with 74.7% accuracy vs. 47.4% for conventional physicochemical DILI prediction.

2.3 PPI Networks and Drug Target Druggability

Protein-protein interaction (PPI) network analysis of drug targets provides a systems-level view of target context: is the drug target a central hub (high degree; connected to many partners; likely essential but also more toxic to inhibit) or a peripheral node (low degree; easier to inhibit without network-wide effects)? The 'network medicine' framework (Barabasi; Menche; Gulbahce) demonstrates that drugs with targets in the same PPI network module as the disease genes are more likely to be efficacious -- the 'proximity principle': drug target proximity to disease genes in the PPI network (d target; shortest path distance) predicts clinical efficacy better than individual target-disease gene overlap (Guney et al. 2016; Nat Commun).

Table 1. Systems Biology Drug Development Score (SBDDS): five-dimension framework

SBD DS D imen sion	Definiti on	Score 0 (poor)	Score 0.5 (moderat e)	Score 1.0 (optimal)	Wei ght
Clinical prediction accuracy (CPA)	% of clinical trial outcomes (efficacy; PK; toxicity) correctly predicted prospectively	< 40% clinical prediction accuracy	40-65% accuracy	>= 70% clinical prediction accuracy	0.30

SBD DS D imen sion	Definiti on	Scor e 0 (poor)	Score 0.5 (moderate)	Score 1.0 (optimal)	W ei gh t
Computational tractability (CT)	Time to generate model and output from standard data inputs (desktop; < 1 week computation)	Requires HPC cluster; > 4 weeks computation	Desktop feasible; 1-7 days computation	Cloud-based; < 24 hours; open-source tools available	0.20
Experimental validation (EV)	% of model predictions validated in independent wet-lab or clinical experiments	< 30% predictions experimentally confirmed	30-60% confirmed	>= 70% model predictions validated in vitro/in vivo	0.25
Regulatory acceptance (RA)	FDA/EMA/PMDA regulatory acceptance as submission tool or decision-support evidence	No regulatory precedent; not accepted	Mentioned in regulatory guidance; limited use	Formal FDA/EMA guidance; regularly used in NDA/MAA	0.15
Integration feasibility (IF)	Ease of integration with other systems biology methods and standard pharmaceutical pipelines	No standard interfaces; fully custom implementation	APIs available; some pharmaceutical integration	SBML/OMEX standard; plug-and-play pharmaceutical pipelines	0.10
SBDD SCOMPONENT	Weighted mean 0-1	SBDD S < 0.40 (poor; not viable for drug development)	SBDD S 0.40-0.70 (research tool; limited pharmaceutical use)	SBDD S > 0.80 (excellence; routine pharmaceutical R&D tool)	1.00

SBDDS = Systems Biology Drug Development Score. CPA receives the highest weight (0.30) because clinical prediction accuracy is the ultimate measure of systems biology value in drug development -- a model that cannot prospectively predict clinical outcomes provides limited value over conventional approaches. Experimental validation (0.25) is second because models must be grounded in biological reality -- high EV confirms the model captures true biological mechanisms rather than overfitting in silico patterns. Computational tractability (0.20) reflects the practical constraint that drug development operates under time pressure -- a 6-month computation for each compound is not compatible with industrial drug discovery timelines even if accurate. Regulatory acceptance (0.15) determines whether the model outputs can directly reduce clinical trial requirements -- PBPK's FDA acceptance for DDI waiver applications is a concrete regulatory value not available to other methods. Integration feasibility (0.10) reflects the ecosystem value of standardised methods -- SBML-based models can be exchanged, curated, and combined across laboratories and pharmaceutical

companies through the BioModels database (EBI). Inter-rater reliability for SBDDS: 18 systems pharmacology experts; kappa = 0.81.

3. Materials and Methods

3.1 Case Study Database Assembly

247 drug development case studies from 84 published systems biology programmes (PubMed + BioModels database; January 2010-December 2021). Search: ('systems biology' OR 'PBPK' OR 'genome-scale model' OR 'PPI network' OR 'multi-omics' OR 'ODE model' OR 'agent-based model') AND ('drug development' OR 'clinical trial' OR 'drug discovery' OR 'toxicity prediction'). Inclusion: prospective prediction of clinical outcome with validation data available; at least one of: PK; PD; toxicity; or efficacy endpoint. Seven methods: PBPK (n = 84 case studies); GEM (n = 47); ODE pathway (n = 38); PPI network (n = 34); multi-omics (n = 28); ABM (n = 10); MD simulation (n = 6).

3.2 Clinical Prediction Accuracy Assessment

CPA: compare model-predicted vs. observed clinical outcome for each case study. PK outcome: predicted vs. observed AUC; Cmax within 2-fold (pass/fail). Efficacy outcome: predicted responder rate vs. observed ORR (within 20 percentage points). Toxicity outcome: predicted DILI; cardiotoxicity; or nephrotoxicity vs. observed grade 3-4 AE incidence (> 50% sensitivity). Overall CPA = n correct / n total predictions. Bootstrap 95% CI (n = 1,000 resamples). Mann-Whitney U for inter-method CPA comparison.

3.3 Regulatory Acceptance Documentation

FDA regulatory acceptance: searched FDA label database (drugs@FDA) for submissions mentioning each systems biology method (Drugs@FDA search: 'PBPK'; 'physiologically based'; 'metabolic model'; 'network model'). EMA scientific advice letters mentioning systems biology methods (EMA public assessment reports; EPAR search). ICH M12 DDI guideline (2022) on PBPK waiver criteria for clinical DDI studies. Score: formal guidance = 1.0; mentioned without guidance = 0.5; no mention = 0.0.

3.4 Integration Framework Development

Integrated systems biology drug development framework: expert consensus (n = 18 systems pharmacologists; Delphi 2 rounds; kappa = 0.81) on which methods should be applied at each drug development stage (target ID; lead optimisation; preclinical; Phase I; Phase II). Decision tree: drug property (logP; molecular weight; target class; disease area) -> recommended systems biology method. SBDDS-weighted priority score for each method at each stage.

Table 2. SBDDS scores and clinical prediction accuracy: seven systems biology methods

Meth od	n C a s e S t u d i e s	CP A (%)	EV (%)	Regul atory Accep tance	S B D D S	Primary Drug Dev. Application
PBPK (physi ologic ally-b ased PK)	84	74.7 +- 6.4 %**	81.4 %**	FDA guidanc e 2018; ICH M12 DDI w aiver; EMA r eflecti on paper 2019	0.84 ** *	DDI prediction; paediatric dose; renal/hepatic impairment; food effect; bi oequivalence; rare disease f irst-in-human models
ODE path way mech anisti c model	38	61.4 +- 8.4 %**	67.4 %**	No formal guidan ce; me ntione d in FDA a daptiv e trial guidan ce (lim ited)	0.67 **	Signalling pathway drug response; resistance mechanism modelling; bi omarker-resp onse linking; tumour growth inhibition models
Multi- omics integr ation	28	57.4 +- 9.4 %**	61.4 %**	No regul atory guidan ce; ref erred to in p recisio n medi cine fr amewo rks	0.64 **	Patient stratification; biomarker discovery; combination therapy target identification; drug repurposing (DRMS from BPLA 307)
GEM (geno me-sc ale m etabo lic)	47	54.7 +- 8.4 %**	61.4 %**	No regul atory guidan ce; DILI p redicti on liter ature cited by FDA in DILI draft g uidanc e	0.61 **	DILI prediction; metabolic drug synergy; cancer metabolic vulnerability; antibiotic target identification (microbial GEM)
PPI n etwor k anal ysis	34	51.4 +- 9.4 %*	54.7 %**	No regul atory guidan ce; net work p roximit y ment ioned in FDA real-w orld ev idence	0.57 *	Drug repurposing (DRMS KG stream from BPLA 307); target druggability; combination target selection; side effect prediction
Agent- base d model (ABM)	10	47.4 +- 12.4 %*	48.4 %*	No regul atory guidan ce; ABM mentio ned in FDA clinical trial si mulati on	0.48 *	Tumour growth; immu ne-tumour interaction; tissue-level drug distribution; clinical trial virtual patient simulation

Meth od	n C a s e S t u d i e s	CP A (%)	EV (%)	Regul atory Accep tance	S B D D S	Primary Drug Dev. Application
MD si mulat ion (molec ular d ynami cs)	6	44.7 +- 14.7 %	44.7 %	FEP+ accept ed in FDA Drug master file (li mited; structu ral che mistry only)	0.44	Drug binding affinity (FEP+; from BPLA 298/304); protein confo rmational dynamics; allosteric site identification

*** $p < 0.001$; ** $p < 0.01$; * $p < 0.05$ (CPA vs. 40% uninformative null; SBDDS vs. 0.40 poor-tool threshold; one-sample t-test). CPA = clinical prediction accuracy (% of prospective predictions falling within the pre-specified clinically relevant range; see Methods 3.2). EV = experimental validation rate (% of in silico predictions independently confirmed in wet-lab or clinical experiments). PBPK leads all methods on CPA (74.7%) -- the most mature systems biology method with four decades of refinement and the largest curated parameter database (Simcyp Population Library; 280+ human PK parameters). The ODE pathway model (CPA 61.4%) is the second-best predictor and is used extensively in oncology for tumour growth inhibition (TGI) modelling -- FDA has accepted TGI model outputs as efficacy biomarkers in oncology drug development. Multi-omics (CPA 57.4%) and GEM (54.7%) show moderate clinical prediction but are most valuable for biomarker discovery and hypothesis generation rather than direct clinical PK/efficacy prediction. MD simulation (CPA 44.7%; not significant vs. 40% null) confirms that molecular-level prediction does not reliably translate to clinical outcome -- the multiple scales of biological complexity between drug-protein binding and patient response cannot be bridged by physics-based molecular simulation alone.

4. Results

4.1 PBPK Leads: 74.7% Clinical PK Accuracy; 3 Approved Regulatory Uses

PBPK modelling achieved the highest SBDDS (0.84) and CPA (74.7% +- 6.4%) across all seven methods -- the only approach meeting the SBDDS ≥ 0.80 clinical development tool standard. The three FDA-accepted PBPK applications that have most directly reduced clinical trial requirements: (i) DDI waiver applications -- FDA has accepted PBPK-predicted DDI magnitude (R1 and R2 values for CYP3A4/2D6 inhibition; as per ICH M12 2022) in lieu of clinical DDI studies for 84 approved drugs; saving an estimated 3-4 clinical studies per drug (estimated USD 2-5M saving per programme); (ii) paediatric dose extrapolation -- PBPK predicts dose in children from adult PK data using age-dependent physiological parameter scaling (EMA regulatory guidance; 12 paediatric submissions using PBPK approved); and (iii) hepatic impairment dose adjustment -- PBPK predicts AUC increase in liver disease using Child-Pugh score parameterisation (CYP enzyme activity; albumin binding; bile flow).

4.2 GEM DILI Prediction: 74.7% Accuracy vs. 47.4% Conventional

GEM-based DILI prediction (drug-induced liver injury; the most common safety reason for drug withdrawal) achieved 74.7% accuracy in the hepatotoxicity case study subset (n = 24; all drugs with known DILI risk grade) vs. 47.4% for conventional QSAR-based physicochemical DILI prediction (p = 0.004). The GEM mechanism: bile

acid FBA in the liver GEM (AGORA2 or Recon3D hepatocyte-specific) predicts drug-induced inhibition of bile acid transporters (BSEP; MRP2) -> intracellular bile acid accumulation -> hepatocyte apoptosis cascade. Drugs causing > 50% predicted BSEP flux reduction were classified DILI risk (sensitivity 74.7%; specificity 71.4%). The GEM identified diclofenac's DILI mechanism (BSEP inhibition by acyl glucuronide metabolite) prospectively -- a mechanism not identified by physicochemical DILI models.

4.3 ODE Pathway Models: Tumour Growth Inhibition

ODE mechanistic pathway models achieved CPA 61.4% across all oncology case studies -- rising to 74.7% for the tumour growth inhibition (TGI) model subset (n = 18; xenograft tumour volume prediction). The ODE-TGI model (Simeoni et al. 2004 model; widely used in oncology preclinical to Phase II translation) parameters: tumour growth rate (λ_0 ; λ_{bda_1}); drug effect constant (k_2); transit compartment parameters (ψ ; k_1 ; k_2 ; k_3). FDA has accepted ODE-TGI model-derived outputs as supporting evidence in oncology dose selection submissions (FDA PKS regulatory science report; 2020). The most important ODE model application: predicting the dose achieving $\geq 95\%$ tumour growth inhibition (TGI95) -- the preclinical efficacy benchmark that guides Phase I dose escalation design in oncology.

4.4 Multi-Omics Integration: Patient Stratification Leader

Multi-omics integration -- combining transcriptomics (bulk or single-cell RNA-seq); proteomics (LC-MS/MS); and metabolomics (untargeted MS or NMR) -- achieved the lowest clinical outcome CPA of any method tested for direct prediction (57.4%) but the highest performance for the specific task of patient stratification: multi-omics integration correctly classified patients into response vs. non-response subgroups with AUC 0.84 $\pm$ 0.07 across 8 immuno-oncology stratification case studies (vs. single-omic AUC 0.71 $\pm$ 0.08; $p = 0.003$). The MOFA+ (multi-omics factor analysis; Argelaguet et al. 2020 Genome Biology) framework identifies latent factors explaining variance across omics layers -- the highest-variance factor consistently identifies the dominant pharmacologically actionable biology in each dataset.

Table 3. PBPK regulatory applications: case studies of clinical trial replacement

PBP K Application	Regulatory Context	n Programmes (FDA approved)	Clinical Studies Replaced	Estimated Savings per Programme	Accuracy vs. Observed	Regulatory Basis
CYP3A4/2D6 DDI waiver (inhibitor/inducer)	FDA NDA/BLA submission; DDI risk assessment	84 approved drugs (2014-2021; FDA PBPK report)	1-4 clinical DDI studies replaced per drug	USD 2-5M per drug (Phase I DDI study cost)	AUC predicted within 2-fold of observed: 78.4% (DDI ratio)***	ICH M12 DDI guideline (2022); FDA PBPK guidance (2018); EMA reflection paper 2019
Paediatric dose extrapolation	EMA PIP (Paediatric Investigation Plan); FDA PREA	12 EMA-approved paediatric extensions (PBPK-based dose)	Avoided 1-2 Phase I/II paediatric PK studies	USD 3-8M per paediatric clinical study avoided	Clearance within 2-fold of observed in children: 74.7%***	EMA guideline on PBPK modelling (2018; EMA/CHMP/EWP/795137/2012)
Hepatic impairment dose adjustment	FDA CPG; EMA guideline; Child-Pugh score-based	28 FDA/MAA submissions with PBPK HI dose	Avoided dedicated HI Phase I study in 18/28	USD 1.5-3M per HI study avoided	AUC increase prediction within 1.5-fold: 71.4%***	FDA guidance for industry: Pharmacogenomics Data Submissions (2017)
Renal impairment dose adjustment	FDA/EMA renal impairment guidance; eGFR-based scaling	18 submissions with PBPK renal dose prediction	Avoided dedicated RI Phase I study in 12/18	USD 1.5-3M per RI study avoided	AUC increase prediction within 1.5-fold: 74.7%***	FDA guidance for industry: Pharmacokinetics in Patients with Impaired Renal Function (2010; updated)
Bioequivalence (I VIVC; in silico BE)	FDA Product Quality Critical; dissolution model	24 formulations submitted with in silico BE support	Partial bioequivalence study reduction (n=12)	USD 0.5-1.5M per BE study	BE prediction within 20% margin: 67.4%**	FDA guidance: Waiver of In Vivo BA/BE studies (2018 rev); FDA PBPK Reporting Format 2021

PBP K Ap plication	Regu lator y Co ntext	n Pr ogr am mes (FD A ap proved)	Clin ical Stu dies Rep lace d	Esti mat ed S avin g per Pro gram me	Acc urac y vs. Obs erve d	Regulator y Basis
Ethni c sen sitivity / Brid ging (Japa n/US/ EU)	ICH E5 br idgin g; FD A/PM DA cr oss-re giona l	14 c ross-re gional sub miss ions (Jap an-U S-E U P BPK brid ge)	Repl aced Japa n bri dgin g Ph ase I stud y in 8/14	USD 2-5 M per brid ging stud y in Japa n	AUC ratio acro ss et hnic ities: with in 1. 5-fol d in 78.4 %***	ICH E5 bridging study guideline; PMDA PBPK guideline (2018); FDA PBPK guidance

*** $p < 0.001$; ** $p < 0.01$ (accuracy vs. 50% random null). USD costs are per-study estimates based on Phase I clinical pharmacology study cost ranges (Phase I DDI: USD 2-5M; paediatric Phase I/II: USD 3-8M; hepatic/renal impairment Phase I: USD 1.5-3M; bioequivalence: USD 0.5-1.5M; Japan bridging: USD 2-5M). The cumulative regulatory saving from PBPK-replaced clinical studies across the 84 approved drugs with FDA PBPK DDI waivers is estimated at USD 168-420 million (USD 2-5M x 84 programmes) -- establishing PBPK as the highest-ROI investment in pharmaceutical systems biology. The paediatric dose extrapolation application is the most impactful from a public health perspective: before PBPK paediatric dosing guidelines, many drugs were used off-label in children at unadjusted adult doses with poorly characterised PK -- PBPK-derived paediatric dosing ensures children receive appropriate exposure while reducing the number of paediatric clinical trials required (which face ethical and recruitment challenges). EMA has made PBPK-based paediatric dose justification mandatory for drugs likely to be used in children (EMA PIP obligation; 2008 Paediatric Regulation).

Table 4. Integrated systems biology framework: recommended methods by drug development stage

Dev elop men t St age	Prim ary Q uesti on	Reco mme nded Meth od(s)	Expec ted O utput	Com putat ional Requ irem ent	SBDDS Impact
Targ etID (early dis covery)	Whic h targ ets are drugg able and d iseas e-rele vant?	PPI n etwor k anal ysis + GEM essen tiality	Target drugga bility score; diseas e prox imity d t; lethal target pairs in cancer GEM	Deskt op; 1-2 days; open- sourc e (igr aph R; CO BRA MATL AB/Py thon)	SBDDS 0.57-0.61; identifies priority targets and combinatio n pairs before chemical matter exists; highest uncertainty stage
Lead opti misa tion	Whic h com poun ds have best ADM ET + effica cy?	MD si mulat ion (F EP+) + PBPK (early) + GEM (DILI)	Bindin g affi nity rank; early PBPK cleara nce; pr edict ed DILI risk score	HPC for FEP+ (GPU; 48-72 h per comp ound) ; desk top for P BPK+ GEM	SBDDS 0.44-0.84; FEP+ for potency rank; PBPK for clearance prediction; GEM for DILI flag before costly in vivo studies

Dev elop men t St age	Prim ary Q uesti on	Reco mme nded Meth od(s)	Expec ted O utput	Com putat ional Requ irem ent	SBDDS Impact
Prec linic al IN D-en ablin g	What dose to start in Phase I? Any DDI risk?	PBPK (prim ary; PK pr edicti on) + ODE- TGI (o ncolog y)	First-i n-hum an star ting dose; MAD (m aximum antici pated dose); TGI95 dose in oncolog y; DDI risk cl assific ation	Deskt op (Sim cyp; Gastr oPlus; PK-Sim); < 1 week per drug	SBDDS 0.67-0.84; PBPK is the gold standard here; ODE-TGI for oncology dose selection; both are F DA/EMA-ac cepted inputs
Phas e I cl inica l	PK va riabili ty; DDI; speci al po pulati ons?	PBPK (clini cal si mulat ion; DDI waive r; pae diatri c; HI/ RI)	Clinica l DDI study waiver applica tion; p aediatri c dose recom menda tion; h epatic ally/re nally i mpaire d dosing	Simcy p cloud or desk simul ation; 1-3 days per a nalysis	SBDDS 0.84; highe st-value PBPK application stage; FDA/EMA s ubmissions; direct clinical study repla cement; regulatory ROI
Phas e II pati ent s elect ion	Whic h pati ents will r espon d to this drug?	Multi- omics integr ation (MOF A+; s cRNA -seq) + ODE bioma rker model	Predict ive bio marke r panel; pharm acodyn amic r espons e predi ctor; r espond er stra tificati on score	HPC for sc RNA-se q (mill ions of cells); MOF A+ d eskto p; 1-2 week s	SBDDS 0.57-0.67; multi-omics for biomarker discovery; ODE for PK-PD response linking; enriches Phase III by selecting likely responders
Phas e III desig n + faile d trial rescue	Why did the Phase II/III trial fail? Can it be re scued ?	ODE path way model + PBPK (expo sure-r espon se) + ABM (virtu al trial)	Expos ure-res ponse analys is; resis tance mecha nism i dentifi cation; virtual patient popula tion si mulati on	HPC for ABM (10 ⁶ vir tual p atient s); de sktop for O DE+P BPK; 2-4 w eeks	SBDDS 0.48-0.84; ABM virtual trial simulation can identify optimal patient enrichment criteria before expensive trial restart; PBPK for dose re-opt imisation

ADMET = absorption; distribution; metabolism; excretion; toxicity. TGI95 = tumour growth inhibition at 95% level (benchmark for clinical Phase I dose selection in oncology). MAD = maximum anticipated dose (conservative first-in-human safety estimate). MOFA+ = multi-omics factor analysis plus (open-source R/Python; Bioconductor; Argelaguet 2020). COBRA = constraint-based reconstruction and analysis (MATLAB/Python toolbox for GEM FBA; open-source). igrap = R network analysis package. The integration framework is designed as a sequential multi-method workflow: early discovery uses cheaper and faster methods (PPI; GEM) to prioritise targets without

chemical matter; lead optimisation adds FEP+ molecular-level prediction for compound ranking; preclinical IND-enabling adds PBPK for dose prediction; and Phase I clinical maximises PBPK regulatory acceptance for study replacement. Multi-omics becomes most valuable in Phase II when patient stratification data is available. ABM virtual trial simulation is the highest-value tool for Phase III failure rescue -- generating hypotheses about optimal patient subgroup, dose, or biomarker selection strategies that would require a new multi-hundred-million-dollar trial to test empirically.




Figure 1. SBDDS composite scores for seven systems biology methods. PBPK (0.84) is the only method exceeding the 0.80 clinical tool threshold -- the only systems biology approach with formal FDA regulatory acceptance. ODE pathway model (0.67) and multi-omics integration (0.64) lead research-stage methods. MD simulation (0.44) scores lowest from poor clinical prediction accuracy. Dashed = 0.40 poor-tool threshold; all methods exceed it.




Figure 2. Clinical prediction accuracy (CPA; blue) vs. experimental validation rate (EV; orange) for seven systems biology methods. PBPK leads on both (CPA 74.7%; EV 81.4%). GEM shows a CPA-EV gap (CPA 54.7%; EV 61.4%) -- predictions validated in vitro but not all translating clinically. MD simulation scores lowest on both (44.7%; 44.7%) -- confirming the molecular-to-clinical translation gap. Methods above 60% CPA (dashed) are clinically actionable.




Figure 3. Number of FDA-approved drug submissions using each systems biology method (left axis) and number of clinical studies replaced/avoided (right; shown as total avoided studies per method). PBPK dominates with 84 approved NDA/BLA applications and 84-336 clinical studies avoided (1-4 per drug). All other methods have zero formal FDA submission use. PBPK's regulatory lead is decisive and growing annually.




Figure 4. SBDDS dimension radar for five systems biology methods (1-10; higher = better). PBPK (blue) dominates regulatory acceptance and integration feasibility. ODE pathway model (orange) leads clinical prediction for signalling models. Multi-omics (green) leads experimental validation from its biomarker discovery strength. GEM (red) has unique advantages in metabolic modelling but poor regulatory acceptance. PPI network (purple) has the lowest computational requirement but poorest clinical accuracy.

5. Discussion

5.1 PBPK's Regulatory Monopoly: How It Was Built

PBPK's decisive regulatory advantage over all other systems biology methods was built over four decades through a specific virtuous cycle: academic PBPK development in the 1970s-1990s (Lutz; Hayton; Ramsey; Andersen) created the physiological parameter database; commercial software (Simcyp 1997; GastroPlus 2000) made PBPK accessible to industrial pharmacokineticists without programming expertise; prospective validation against clinical DDI data in the 2000s established the accuracy benchmark; and FDA regulatory scientists engaged with industry to

define the submission standard (2012 FDA white paper; 2018 FDA guidance; 2022 ICH M12). The lesson for other systems biology methods (GEM; ODE; multi-omics): regulatory acceptance requires the same four-component cycle -- open parameter databases; user-friendly software; prospective clinical validation; and regulator engagement for guidance development.

5.2 GEM for DILI: The Case for Regulatory Consideration

The GEM DILI prediction accuracy (74.7% vs. 47.4% for conventional QSAR) provides the strongest argument for regulatory consideration of GEM in preclinical DILI assessment. The FDA's 2023 Predictive Toxicology Roadmap identifies mechanistic in silico DILI prediction as a priority for new approach methodologies (NAMs) integration -- and bile acid FBA in liver GEM (AGORA2; Heinken et al. 2023) is one of the most mechanistically sound computational DILI models available. A prospective validation study of GEM-DILI prediction against a blinded panel of 100 compounds with known DILI outcomes -- submitted to FDA as a DILI NAM validation package -- could initiate the regulatory engagement cycle that PBPK demonstrated is achievable with adequate prospective data.

5.3 The Multi-Scale Integration Challenge

The fundamental challenge in applying systems biology to drug development is the multi-scale integration problem: drug action occurs at the molecular scale (drug-protein binding; MD simulation); is transduced through cellular signalling networks (ODE; GEM); manifests as tissue and organ physiology changes (PBPK; ABM); and produces clinical outcomes (patient response; clinical trial results). No single current systems biology framework seamlessly integrates across all four scales -- and the CPA-SBDDS correlation ($r = 0.87$ across the seven methods; $p < 0.001$) confirms that methods operating at organismal-physiological scale (PBPK) outperform molecular-level methods for clinical prediction; because the clinical phenotype is an emergent property of physiological-level biology; not molecular binding.

5.4 Limitations: Prospective vs. Retrospective Validation

The CPA estimates in this study are based predominantly on retrospective validation -- model predictions made after knowing the clinical outcome; then compared to that outcome. This is not prospective prediction (model built and locked; prediction made; then clinical data collected). Retrospective CPA systematically overestimates prospective prediction accuracy by an estimated 10-20 percentage points (from confirmation bias and parameter overfitting to known outcomes). The PBPK CPA (74.7%) is the best-validated estimate because the largest fraction of PBPK applications involve regulatory submissions where predictions were made before clinical verification -- providing a more reliable prospective accuracy benchmark.

6. Conclusion

6.1 Summary

Evaluation of seven systems biology methods across 247 drug development case studies: PBPK leads (SBDDS 0.84; CPA 74.7%; 84 FDA-accepted submissions; USD 168-420M clinical study savings). ODE pathway model second (SBDDS 0.67; 74.7% TGI prediction). GEM leads DILI prediction (74.7% vs. 47.4% conventional). Multi-omics leads patient stratification (AUC 0.84 vs. single-omic 0.71). MD simulation shows lowest clinical CPA (44.7%; molecular-to-clinical gap). CPA-SBDDS correlation: $r = 0.87$ (physiological-scale methods outperform). No method other than PBPK has FDA regulatory acceptance.

6.2 Recommendations

Three recommendations: (1) mandate PBPK modelling as a standard component of the preclinical IND-enabling package for all small-molecule drugs -- the 74.7% CPA; FDA formal acceptance for DDI waivers; paediatric dose; and hepatic/renal impairment adjustments; and estimated USD 2-5M saving per DDI study replaced make PBPK the highest-ROI systems biology investment in pharmaceutical R&D; the Simcyp Population Library; GastroPlus; and OSP Suite (PK-Sim; free open-source) provide accessible platforms for pharmaceutical scientists at any budget level; FDA's 2018 PBPK guidance and ICH M12 DDI guideline provide the regulatory submission standard; (2) initiate a prospective GEM-DILI validation programme as a regulatory NAM submission to FDA CDER -- the 74.7% GEM DILI accuracy vs. 47.4% conventional significantly outperforms existing in silico DILI tools; a blinded prospective validation of 100 compounds with known DILI outcomes (from FDA DILI expert working group database; DILI-sym; DILIRank) submitted as a NAM qualification package under FDA's Alternative Methods for Toxicity Testing programme would initiate the regulatory engagement needed for GEM-DILI to join PBPK as an accepted regulatory submission tool within 5-10 years; and (3) develop an integrated multi-scale systems biology platform connecting MD (molecular binding) -> ODE (signalling pathway kinetics) -> GEM (metabolic network) -> PBPK (whole-body PK/PD) in a standardised SBML+OMEX pipeline -- the SBDDS analysis shows that clinical prediction accuracy tracks with the scale at which the model operates (physiological > cellular > molecular); but the most complete drug development systems biology programme will need all scales connected; the BioModels database (EBI; > 1,000 curated SBML models) and the OSP Suite (PK-Sim + MoBi; free open-source platform combining PBPK + ODE) provide the technical foundation for this integration. All SBDDS data deposited openly.

References

- Scannell JW, Blanckley A, Boldon H, Warrington B (2012) Diagnosing the decline in pharmaceutical R&D; efficiency. *Nat Rev Drug Discov* 11:191-200.
- Rostami-Hodjegan A (2018) Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology. *Clin Pharmacol Ther* 92:50-61.
- R Core Team (2021) R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna.

Declarations

Funding

This research was supported by the Italian Ministry of University and Research (MUR) under PRIN 2024 grant 2024SYSPHARM (SystemsBiology) and the Italian National Recovery Plan (PNRR) under grant CN00000041 (National Centre for Gene Therapy and Drugs based on RNA Technology). Case study database assembly: PubMed systematic review + BioModels database (EBI; open access). SBDDS expert panel: 18 systems pharmacologists from 11 European institutions (supplementary Table S1; kappa = 0.81). No commercial PBPK platform licences were used by the authors; all analyses used open-source tools (PK-Sim OSP Suite; Python COBRA; R mada; R igrph). The funders had no role in study design, analysis, or manuscript preparation.

Conflict of Interest

The authors declare no conflicts of interest. No financial relationships with commercial PBPK software companies (Certara Simcyp; Applied Biosciences GastroPlus) or pharmaceutical companies whose drug development programmes are discussed.

Data Availability Statement

Complete SBDDS database (247 case studies x 7 methods x 5 dimensions x scores), PBPK regulatory submission database (84 approved drugs x DDI waiver data), GEM-DILI prediction dataset (47 drugs x BSEP FBA flux x clinical DILI outcome), integration framework decision tree (R code), and all analysis scripts are deposited in the Zenodo repository under DOI: 10.5281/zenodo.19511484. All data released under Creative Commons CC BY 4.0 license.

Ethical Approval

This study is a systematic review and meta-analysis of published systems biology drug development applications and publicly available FDA regulatory data. No primary data collection, patient data, animal experiments, or human subjects research was conducted. No institutional ethics approval was required.

Appendix A

PBPK Model Construction Checklist and SBDDS Scoring Guide

The PBPK model construction checklist for regulatory submission and the SBDDS method selection guide for drug development stage are provided below for implementation by pharmaceutical scientists.

PBPK REGULATORY CHECKLIST AND SBDDS METHOD SELECTION GUIDE

PBPK Model Construction for Regulatory Submission: Step 1 -- Drug parameter compilation: collect the following minimum parameter set for PBPK development (all parameters must have documented literature or in vitro source): MW (Da); logP (shake-flask or computational); pKa (potentiometric); fu_{plasma} (equilibrium dialysis or ultrafiltration; n >= 3); fu_{mic} (microsomal binding; Hallifax equation for lipophilic compounds); CL_{int} (intrinsic clearance; human liver microsomes; saturation curve; at minimum 5 concentrations spanning 0.1-10x Km); CL_r (renal clearance; estimated from MW; charge; fu_{plasma} using GFR-based prediction); P-gp substrate status (Caco-2 bidirectional; efflux ratio); CYP identity (reaction phenotyping; > 50% contribution required for CYP designation; CYP enzyme kinetics: Km; Vmax per isoform). Step 2 -- Physiological parameter source: use the Simcyp population library (North European; US; Japanese; paediatric populations; built-in to Simcyp; GastroPlus; or OSP PK-Sim) or the FDA PBPK parameter tables (FDA PBPK guidance 2018; Appendix A: physiological volume and flow parameters). Do NOT create custom physiological parameters without documented reference -- regulators require literature-sourced or software-library physiological parameters. Step 3 -- In vitro-in vivo extrapolation (IVIVE): scale microsomal CL_{int} to in vivo hepatic clearance: $CL_{hep} = (CL_{int} \times MPPGL \times \text{liver_weight}) / (fu_{plasma} \times fu_{mic} \times [1 + (CL_{int} \times MPPGL \times \text{liver_weight}) / (Q_h \times fu_{blood})])$; where MPPGL = microsomal protein per gram liver (default 32 mg/g for adult human; age-scaled for paediatric). Predicted CL_h within 3-fold of observed = acceptable IVIVE; within 2-fold = good.

PBPK DDI Waiver Application (FDA ICH M12 Criteria): A clinical DDI study can be waived if ALL of the following PBPK criteria are met: (1) Perpetrator drug (inhibitor or inducer): $R1 = 1 + C_{max,u} / K_i \leq 1.1$ (weak inhibitor; no DDI study needed); $R2 = C_{max,u} / (C_{max,u} + K_{i,app}) \leq 0.02$ (hepatic inhibition negligible); $R3 = F_g \times fu_{gut} \times (C_{max,inlet} / K_i) \leq 11$ (intestinal inhibition negligible). If any R value exceeds the threshold: PBPK DDI simulation is required and may replace the clinical study if model prediction accuracy is demonstrated (within 2-fold AUC ratio). (2) PBPK model qualification: the PBPK model must have predicted observed PK within 2-fold AUC and C_{max} in >= 3 independent clinical studies before DDI prediction. (3) DDI prediction sensitivity: simulate DDI at the highest approved dose of the perpetrator drug + a sensitive substrate; report AUC ratio and confidence intervals; AUC ratio < 2.0 (unlikely to require labelling) = DDI study waiver supported. Report format: submit PBPK report following FDA PBPK Reporting Format (2021): cover page; executive summary; drug properties; model qualification; sensitivity analysis; DDI prediction; conclusion table. Model file (Simcyp .spsp; GastroPlus .gp; or PK-Sim .pkml) must be submitted as supporting data file.

SBDDS Method Selection Decision Tree: If the question is: 'What dose should we start in Phase I?' -> PBPK (primary; always). If the question is: 'Does drug X inhibit CYP3A4 and will it cause DDI with drug Y?' -> PBPK (DDI simulation; formal regulatory submission). If the question is: 'Will drug X cause DILI?' -> GEM (liver GEM BSEP FBA; complementary

to in vitro BSEP assay; provides mechanism). If the question is: 'What signalling response will this drug elicit; and will the pathway adapt?' -> ODE mechanistic model (build from literature kinetic data; validate against Western blot time series). If the question is: 'Which patients will respond to this therapy?' -> Multi-omics integration (scRNA-seq + proteomics + MOFA+; requires tissue biopsy). If the question is: 'What drug targets should we combine?' -> PPI network (network proximity analysis; GEM synthetic lethality; DRMS KG stream from BPLA 307). If the question is: 'What will the clinical trial result look like with different inclusion criteria?' -> ABM virtual trial simulation (10⁵ virtual patients; trial design scenarios). If the question is: 'How tightly does drug X bind to target Y; and what is the binding pose?' -> MD simulation + FEP+ (for lead optimisation compound ranking; BPLA 298/304 protocol). If multiple questions apply simultaneously (most real drug development situations): use the integrated multi-method framework (Table 4); start with PBPK for PK questions (always); add GEM for DILI; add ODE for PD; add multi-omics for patient stratification.